Indication
Recurrent Uterine Cancer
1 clinical trial
3 products
Clinical trial
Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine CancerStatus: Active (not recruiting), Estimated PCD: 2026-12-04
Product
RP-6306Product
CarboplatinProduct
Paclitaxel